Oxford Biomedica

Oxford BioMedica (OXB) is a prominent organization specializing in genetic and cellular therapy, with a focus on the development of transformative treatments for grave illnesses. They have established an advanced lentiviral vector delivery system known as LentiVector®, which is utilized for the creation of in vivo and ex vivo products in collaboration with partners as well as in-house. The company has curated a valuable proprietary collection of potential gene and cell therapy products in the fields of oncology, ophthalmology, and CNS disorders. Furthermore, they have formed strategic alliances with major entities such as Novartis, Sanofi, GSK, and Orchard Therapeutics, in which they hold long-term financial interests in potential gene and cell therapy advancements.